Indication

Parsabiv™ (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Parsabiv™ has not been studied in adult patients with parathyroid cancer, primary hyperparathyroidism, or with CKD who are not on hemodialysis and should not be used in these patients.

Read More

Contact Us

If you have questions about:

Parsabiv™ or medical questions: call 1-800-77-AMGEN (1-800-772-6436)

Coverage and reimbursement questions: call 1-800-272-9376